31. An antigenic polypeptide of at least 7 amino acids of the polypeptide sequence A3 of factor VIII, having an amino acid sequence selected from the group consisting of a sequence fragment contained between arginine 1652 and arginine 1696 inclusive, a sequence fragment contained between threonine 1739 and aspartic acid 1831 inclusive, and a sequence fragment contained between glutamic acid 1885 and arginine 1917 inclusive.

32. An antigenic polypeptide according to Claim 31, having an epitope selected from the group consisting of:

the epitope contained between arginine 1652 and tyrosine 1664 (SEQ ID No:1), the epitope contained between aspartic acid 1681 and arginine 1696 (SEQ ID No:2), the epitope contained between threonine 1739 and tyrosine 1748 (SEQ ID No:3), the epitope contained between asparagine 1777 and phenylalanine 1785 (SEQ ID No:4), the epitope contained between glutamic acid 1794 and tyrosine 1815 (SEQ ID No:5), the epitope contained between methionine 1823 and aspartic acid 1831 (SEQ ID No:6), the epitope contained between glutamic acid 1885 and phenylalanine 1891 (SEQ ID No:7), the epitope contained between glutamic acid 1893 and alanine 1901 (SEQ ID No:8), and the epitope contained between aspartic acid 1909 and arginine 1917 (SEQ ID No:9).

33. Antigenic polypeptide according to Claim 31, containing at least either tyrosine or histidine linked.

34. A conformational epitope containing at least two different epitopes of Claim 32.

35. A conformational epitope containing at least two different epitopes each of, said epitopes, containing at least either tyrosine or histidine linked to at least two other amino acids

in sequence from an amino acid sequence selected from the group consisting of a sequence fragment contained between arginine 1652 and arginine 1696 inclusive, a sequence fragment contained between threonine 1739 and aspartic acid 1831 inclusive, and a sequence fragment contained between glutamic acid 1885 and arginine 1917 inclusive.

36. A complex comprising a carrier protein or a carrier peptide linked to the fragment of Claim 31 or the conformational epitope of Claim 35.

37. An inhibitor of factor VIII, which exhibits an immunoaffinity for an antigenic polypeptide of at least 7 amino acids of the polypeptide sequence A3 of factor VIII, having an amino acid sequence selected from the group consisting of a sequence fragment contained between arginine 1652 and arginine 1696 inclusive, a sequence fragment contained between threonine 1739 and aspartic acid 1831 inclusive, and a sequence fragment contained between glutamic acid 1885 and arginine 1917 inclusive or a conformational epitope containing at least two different epitopes each of said epitopes, containing at least either tyrosine or histidine linked to at least two other amino acids in sequence from an amino acid sequence selected from the group consisting of a sequence fragment contained between arginine 1652 and arginine 1696 inclusive, a sequence fragment contained between threonine 1739 and aspartic acid 1831 inclusive, and a sequence fragment contained between glutamic acid 1885 and arginine 1917 inclusive.

38. An anti-inhibitor, which is directed against an inhibitor of factor VIII, which exhibits an immunoaffinity for an antigenic polypeptide of at least 7 amino acids of the polypeptide sequence A3 of factor VIII, having an amino acid sequence selected from the

group consisting of a sequence fragment contained between arginine 1652 and arginine 1696 inclusive, a sequence fragment contained between threonine 1739 and aspartic acid 1831 inclusive, and a sequence fragment contained between glutamic acid 1885 and arginine 1917 inclusive or a conformational epitope containing at least two different epitopes each of, said epitopes, containing at least either tyrosine or histidine linked to at least two other amino acids in sequence from an amino acid sequence selected from the group consisting of a sequence fragment contained between arginine 1652 and arginine 1696 inclusive, a sequence fragment contained between threonine 1739 and aspartic acid 1831 inclusive, and a sequence fragment contained between glutamic acid 1885 and arginine 1917 inclusive.

39. A pharmaceutical composition comprising at least one element selected from the group consisting of the fragment of Claim 31, the conformational epitope of Claim 35, inhibitor of Claim 37 and the anti-inhibitor of Claim 38 and an acceptable pharmaceutical vehicle.

40. A diagnostic and/or purification device comprising at least one element selected from the group consisting of the fragment of Claim 31, the conformational epitope of Claim 35, inhibitor of Claim 37 and the anti-inhibitor of Claim 38.

41. A method for therapeutic treatment/prevention of an immune disorder induced by inhibitors of factor VIII, inhibitors of the binding of factor VIII to the von Willebrand factor or inhibitors of the binding of factor VIII to membrane phospholipids, said method comprising administering the pharmaceutical composition of Claim 39 to a patient presently or potentially having the immune disorder in an amount effective to treat or prevent the immune disorder.

42. A process for obtaining an inhibitor of factor VIII, comprising the steps of:

selecting an element selected from the group consisting of the fragment of Claim 31, the conformational epitope of Claim 35, and a complex of the foregoing;

attaching the element to a solid support of a chromatography column;

passing a physiological liquid from a patient, which liquid contains inhibitors of factor VIII, through said chromatography column;

eluting said column; and

collecting the fraction containing inhibitors of factor VIII which have exhibited an immunoaffinity with at least one of said element.

43. A process for identifying anti-inhibitors of factor VIII, comprising the steps of:

attaching an inhibitor according to Claim 37 to a solid support of a chromatography column;

passing a physiological liquid from a patient, which liquid contains anti-inhibitors of factor VIII, through said chromatography column;

eluting said column; and

collecting the fraction containing anti-inhibitors of factor VIII which have exhibited an immunoaffinity with inhibitors of factor VIII.

IN THE ABSTRACT:

After the claims of the specification, please insert the attached abstract.

REMARKS

Claims 1-30 have been replaced with Claims 31-42. A sequence listing has been incorporated in the specification in the form of paper as well as a diskette. An abstract has